PROTACs, molecular glues and other degraders

BCL6 PROTAC 15.

BCN-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.Appearance:Viscous liquidIC50&amp: Target:PEGs Alkyl/etherIn Vitro:PROTACs contain two different ligands connected by a linker: one is a ligand for an E3

BCN-PEG4-NHS ester is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.Appearance:Viscous liquidIC50&amp: Target:PEGs Alkyl/etherIn Vitro:PROTACs contain two different ligands connected by a linker: one is a ligand for an E3

BETd-246 is a second-generation and PROTAC -based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET , exhibiting superior selectivity, potency and antitumor activityIn VitroBETd-246 treatment (0-100 nM, 1-3 h) causes a

BETd-246 is a second-generation and PROTAC -based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET , exhibiting superior selectivity, potency and antitumor activityIn VitroBETd-246 treatment (0-100 nM, 1-3 h) causes a

BETd-246 is a second-generation and PROTAC -based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET , exhibiting superior selectivity, potency and antitumor activityIn VitroBETd-246 treatment (0-100 nM, 1-3 h) causes a

BETd-246 is a second-generation and PROTAC -based BET bromodomain (BRD) inhibitor connected by ligands for Cereblon and BET , exhibiting superior selectivity, potency and antitumor activityIn VitroBETd-246 treatment (0-100 nM, 1-3 h) causes a

InformationBI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor

InformationBI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor

InformationBI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor

InformationBI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor

InformationBI-3802 BI-3802 is a highly potent oncogenic transcription factor BCL6 degrader with strong de-repression of target genes anti-proliferative effects. BI-3802 inhibits the BTB domain of BCL6 with IC50 of ≤3 nM. BI-3802 exhibits antitumor